Introduction: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.
William HK Schilling, James J. Callery, Walter Taylor, Mavuto Mukaka, Maneerat Ekkapongpisit, James A Watson, Arjun Chandna, Salwaluk Panapipat, Jaruwan Tubprasert, Prayoon Yuentrakul, Naomi Waithira, Tanya Cope, Mehul Dhorda, Cintia Cruz, Lorenz von Seidlein, Joanne Milton, Martin Llewelyn, Amanda Adler, Kesinee Chotivanich, Phaik Yeong Cheah, Elizabeth A. Ashley, Mayfong Mayxay, Arjen M. Dondorp, Weerapong Phumratanaprapin, Nicholas Day, Sir Nicholas White
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, Janneke van ’t Hooft, Sherief Abd‐Elsalam, Ehab Fawzy Abdo, Benjamin S. Abella, Javed Akram, Ravi K. Amaravadi, Derek Angus, Yaseen M. Arabi, Shehnoor Azhar, Lindsey R. Baden, Arthur W. Baker, Leïla Belkhir, Thomas Benfield, Marvin A. H. Berrevoets, Cheng‐Pin Chen, Tsung‐Chia Chen, Shu‐Hsing Cheng, Chien‐Yu Cheng, Wei‐Sheng Chung, Yehuda Z. Cohen,
Discussion(0)
No comments yet. Be the first to comment.